Dexcom CGM Worn in Outer Space as Part of First-of-its-Kind Polaris Dawn Mission
September 10 2024 - 6:29AM
Business Wire
- Dexcom CGM is being worn by astronauts in space as part of the
Polaris Dawn mission, which aims to better understand the effects
of spaceflight on human health
DexCom, Inc. (Nasdaq: DXCM), the global leader in real-time
continuous glucose monitoring for people with diabetes, today
announced the Dexcom G6 Continuous Glucose Monitoring (CGM) System
is being worn by astronauts in space as part of the Polaris Dawn
mission, which launched this morning and aims to better understand
the effects of spaceflight on human health.
While in orbit, the Polaris Dawn crew will conduct scientific
research designed to advance both human health on Earth and our
understanding of human health during long-duration spaceflights.
Given that one in ten1 people globally live with diabetes, it’s
essential to understand the impact of space travel on human health
to ensure it is accessible and inclusive of all people, including
those living with diabetes and other chronic health conditions.
“As the pioneer in glucose sensing, Dexcom has been responsible
for bringing almost every major ‘first’ to market for the CGM
category. This health research driven mission marks another first
for Dexcom, with our industry leading CGMs being worn by astronauts
in outer space,” said Jake Leach, executive vice president and
chief operating officer at Dexcom. “We are thrilled to play a role
in building a future where people with diabetes are empowered to
accomplish anything they set their minds to–including the
possibility of exploring outer space–without being held back by
their condition.”
Dexcom CGM systems consist of a small, wearable sensor that
continually measures and sends glucose data wirelessly to a smart
device* or receiver, giving users accurate2 real-time glucose data
without the need to scan or prick their finger.† Dexcom CGMs have
industry-leading remote monitoring and reporting capabilities and
also provide personalized, actionable insights that empower people
to solve important health challenges.
Over their five days in space, the Polaris Dawn crew will
conduct around 40 scientific experiments, including several to
better understand the effects of spaceflight on glucose health.
Labfront, a platform assisting health researchers in collecting and
analyzing physiological data, is collaborating with Dexcom to
provide advanced analytics for the data collected using Dexcom CGM.
The research will explore how microgravity, fluid shifts, and blood
flow restriction exercises impact glucose regulation.
“Glucose is a critical biomarker for understanding metabolic
responses in space, and analyzing its dynamics and interplay with
other physiological biomarkers will provide invaluable data for
this mission’s scientific objectives,” said Dr. Andrew Ahn,
assistant professor at Harvard Medical School and chief medical
officer at Labfront.
Dexcom has long believed that understanding glucose is integral
to overall health and wellness. Dexcom recently launched Stelo, the
first glucose biosensor cleared by the FDA for use without a
prescription and available for use by all adults not using insulin
in the U.S. Dexcom is the most recommended‡ CGM brand by both
patients3 and healthcare providers,4 offering a portfolio of
glucose biosensors designed to address the needs of people with all
types of diabetes and prediabetes.
Visit Stelo.com today to get started with
Stelo, or do a benefits check to see if you are eligible for Dexcom
G7 at Dexcom.com/Start.
About DexCom, Inc.
DexCom, Inc. empowers people to take real-time control of health
through innovative continuous glucose monitoring (CGM) systems.
Headquartered in San Diego, Calif., and with operations across
Europe and select parts of Asia/Oceania, Dexcom has emerged as a
leader of diabetes care technology. By listening to the needs of
users, caregivers, and providers, Dexcom works to simplify and
improve diabetes management around the world. For more information
about Dexcom CGM, visit www.dexcom.com.
*Smart device sold separately. For a list of compatible devices,
visit www.Dexcom.com/compatibility. †Fingersticks required for
diabetes treatment decisions if symptoms or expectations do not
match readings. ‡Based on a comparison in NPS scores across major
CGM brands.
1 International Diabetes Federation. IDF Diabetes Atlas, 10th
edn. Brussels, Belgium: 2021. Available at:
https://www.diabetesatlas.org. 2 Welsh JB, et al. J Diabetes Sci
Technol. 2024;18(1):143-7. 3 dQ&A US Q1 2023 US Diabetes
Connections Patient Panel Report. 4 Seagrove HCP Survey Q2
2022.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240827030657/en/
Media Contact
mediarelations@dexcom.com
Investor Contact Sean
Christensen 858-203-6657 sean.christensen@dexcom.com
DexCom (NASDAQ:DXCM)
Historical Stock Chart
From Aug 2024 to Sep 2024
DexCom (NASDAQ:DXCM)
Historical Stock Chart
From Sep 2023 to Sep 2024